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It is generally accepted that the combination of both Plasmodium falciparum parasite and human host factors is involved
in the pathogenesis of complicated severe malaria, including cerebral malaria (CM). Among parasite products, the malarial
pigment haemozoin (HZ) has been shown to impair the functions of mononuclear and endothelial cells. Different CM models
were associated with enhanced levels of matrix metalloproteinases (MMPs), a family of proteolytic enzymes able to disrupt
subendothelial basement membrane and tight junctions and shed, activate, or inactivate cytokines, chemokines, and other MMPs
through cleavage from their precursors. AmongMMPs, a good candidate for targeted therapy might beMMP-9, whosemRNA and
protein expression enhancement as well as direct proenzyme activation by HZ have been recently investigated in a series of studies
by our group and others. In the present paper the role of HZ and MMP-9 in complicated malaria, as well as their interactions, will
be discussed.
1. Introduction
Among protozoan parasites of the genus Plasmodium, P. fal-
ciparum is the most deadly agent of human malaria, causing
a broad spectrum of clinical manifestations ranging from
asymptomatic to severe multiorgan disease. Despite recent
major efforts by the research community, malaria remains
one of the major diseases in poor areas, including Sub-
Saharan Africa and South-East Asia. It is associated with
several million clinical cases per year and leads annually to
over one million deaths [1, 2]. The pathophysiology of severe
malaria complications is not well understood. In some cases,
including cerebral malaria (CM), renal failure, lung patholo-
gy and malaria during pregnancy, it appears associated with
cytoadherence and sequestration of P. falciparum-parasitized
red blood cells (pRBCs) to vascular endothelium, leading to
microcirculatory obstruction, tissue hypoxia, and metabolic
disturbances [3–5]. In some cases additional leukocyte
extravasation has been reported [6, 7].
As described in the following sections, either pRBCs
or parasite products such as haemozoin (HZ, malarial
pigment), a lipid-enriched ferriprotoporphyrin IX crystal
derived from haemoglobin catabolism by the parasite [8],
can modulate the functions of mononuclear and endothelial
cells and promote the production of proinflammatory
molecules and other soluble factors, including matrix metal-
loproteinases (MMPs). MMPs are a well-known family of
proteolytic enzymes able to disrupt subendothelial basement
membranes [9, 10], to destroy tight junctions [11], and to
shed, activate, or inactivate cytokines, chemokines, and other
MMPs through cleavage from their precursors [12–14]. In
the last decade, growing evidence on involvement of MMPs
in falciparum malaria became available: human postmortem
studies showed enhanced protein levels of MMP-1 in brains
of CM patients [15], whereas MMP-8 was found increased
in plasma of severe malaria patients [16]; additionally,
activation of the human MMP-9 gene by P. falciparum has
been reported in microarray studies on whole blood from
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Figure 1: Effects of phagocytosis of HZ on human monocyte functions.
children with malaria [17]. Interestingly, a role for MMPs
duringmalaria is suggested also by evidence from nonhuman
models of CM: in the brain of mice infected by P. Berghei
ANKA, the etiological agent of murine CM, increased MMP-
2, MMP-7, and MMP-9 levels, and pro-MMP-9 activation
were found [18, 19].
The present paper will explore the effects of HZ on
functions of mononuclear and endothelial cells, focusing on
regulation of human MMP-9, which at present among the
malaria-related MMPs is the most studied and could be a
potential target for adjunctive therapy of complicated severe
malaria.
2. Effects of HZ on Human Mononuclear and
Endothelial Cells
HZ is a birefringent crystalline material made of Fe3+-
Protoporphyrin IX dimers that derives from the degra-
dation of haemoglobin by intraerythrocytic Plasmodium
[8]. Unpurified HZ contains also unspecifically attached
polyunsaturated fatty acids (PUFAs) such as arachidonic and
linolenic acids, originating from membranes of Plasmodium
digestive vacuoles [20]. The presence in unpurified HZ of
large quantities of ferric haem with small amounts of free
iron makes HZ a generator of oxidative radicals capable of
forming lipoperoxides or other breakdown products from
PUFAs (quasilipoxygenase activity) [21]. Analysis of the lipid
fraction isolated from native HZ showed large amounts
of hydroxyeicosatetraenoic acids (HETEs), hydroxyoctadeca-
dienoic acids (HODEs), and the terminal aldehyde 4-hydrox-
ynonenal (4-HNE) [22].
HZ is avidly phagocytosed by human monocytes, and
the fatal risk for patients with severe falciparum malaria has
been reported to be directly proportional to levels of HZ-
containing monocytes in peripheral blood [25]. After phago-
cytosis of HZ, several monocyte functions are dramatically
impaired, as shown in Figure 1. The effects of HZ on human
monocytes are either inhibiting or stimulating. A detrimental
case of functional inhibition led by HZ phagocytosis is
represented by immunodepression. As evidenced from in
vitro studies, HZ-fed human monocytes showed impairment
of repeated phagocytosis [26], bacterial killing abilities [27],
and oxidative burst [28]. Additionally HZ-laden monocytes
did not respond to IFN-gamma stimulation and failed
in MHC Class II expression, with following disturbances
in antigen presentation [29]. These effects appear to be
dependent on the lipid moiety of HZ, and low doses of 4-
HNE have been reported to mimic HZ action by inhibiting
the IFN-gamma-mediated MHC Class II expression [30].
On the contrary, the inhibitory role of HZ on monocyte
differentiation/maturation to dendritic cells is less clear, since
similar in vitro studies by different authors led to opposite
results, showing either inhibition [31] or enhancement
[32, 33] of differentiation/maturation to dendritic cells. HZ
appears also to be related indirectly to anaemia, as HZ-
fed monocytes are not able to coordinate the maturation
of erythroid precursors; also in this case a role for 4-
HNE in HZ-dependent inhibition of erythropoiesis has been
proposed [34]. Regarding the stimulating effects of malarial
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pigment, HZ-laden monocytes have been shown to overpro-
duce a large series of proinflammatory molecules, including
cytokines (TNF, IL-1 beta, and IL-1RA), chemokines (IL-
8/CXCL8, ENA-78/CXCL5, GROα, GROβ, GROγ, MIP-
1α, MIP-1β, and MCP-1) and the cyto/chemokine-related
proteolytic enzyme MMP-9 [23, 35–38]. The lipid moiety of
HZ appears to be responsible for these effects, and a major
role for 15-HETE has been proposed. Due to the important
direct connections to MMP-9, the mechanisms underly-
ing the HZ-triggered pro-inflammatory response will be
deeply discussed in a following dedicated section. Curiously,
although HZ compromises a large number of monocyte
functions, leading to rapid inflammatory response, it has
been recently shown that HZ-laden monocytes do not
undergo apoptosis. To explain such an apparent dichotomy,
a role for heat shock protein-27 (HSP-27), a chemokine-
dependent molecule with antiapoptotic properties, has been
recently proposed by our group. Indeed, in two models
in vitro we showed HZ-dependent upregulation of HSP-27
either in immunopurified monocytes from peripheral blood
or in the THP-1 monocytic cell line [38, 39].
Anyway, phagocytic cells such as monocytes are not the
only human cells which appear to be influenced by HZ. Few
data are also available on direct alterations of the human
endothelial cell phenotype by HZ. Such a change might
be dramatically detrimental during CM, since endothelial
cells are a crucial component of the blood-brain barrier
(BBB). At present, HZ has been reported to enhance either
basal or cytokine-induced levels of adhesion molecules
[40, 41] and to inhibit the release of the vasoconstrictor
mediator ET-1 [42–44]. Additionally, recent evidence from
human microvascular endothelial cells (HMECs) as well as
human umbilical vein endothelial cells (HUVECs) showed
enhancement or de novo induction of protein expression
and activity of several MMPs, including MMP-1, MMP-3,
and MMP-9. This topic will be deepened in the following
sections.
3. Involvement of MMP-9 in Complicated
Severe Malaria
MMP-9 is produced by several cells, including mononuclear
and endothelial cells.
Structurally, MMP-9 shares with the other members of
the MMP family the following conserved domains: a prodo-
main, an active domain, a Zn2+-binding domain and a car-
boxyterminal haemopexin domain (which is absent inMMP-
7 and MMP-26). In addition MMP-9, as well as the other
gelatinaseMMP-2, has a gelatin-binding fibronectin domain,
composed of three fibronectin repeats, inserted between the
active-site domain and the Zn2+-binding domain, plus an
additional collagen type V domain in a particular hinge
region. The Zn2+-binding domain, which contains three his-
tidines responsible for the coordination of the catalytic Zn2+
ion, forms the active site with the active domain and is
required for the enzymatic activity. The fourth ligand of the
Zn2+ ion is a cysteine of the prodomain. This propeptide can
be removed by proteolysis or distorted by substrate binding.
The haemopexin domain plays a role in the substrate
specificity and is important for the binding of the tissue
inhibitors of metalloproteinases (TIMPs). The fibronectin
repeats are related to gelatin, laminin, and collagens I/IV
binding [9, 10, 45].
In the last decade, few evidence of direct involvement of
MMP-9 in severe malaria has been reported. Activation of
the human MMP-9 gene by P. falciparum has been shown in
microarray studies on whole blood from children with severe
malaria [17], whereas MMP-9 increases in cerebrospinal
fluid levels were not apparent, possibly because of the
enzyme’s tight association with the extracellular matrix [46].
At present no studies of MMP-9 in human postmortem brain
tissues have been reported, but MMP-9 levels have been
shown to be strongly upregulated in C57BL/6 mice brain
infected with P. berghei ANKA, a murine model of CM
sharing similar characteristics with human CM. Elevated
MMP-9 levels were selective for the central nervous system,
where they were found associated with the vasculature
and parenchyma whereas immunohistochemistry showed
that higher amounts of MMP-9 were produced by cells of
monocytic lineage (CD11b+) [18].
Activation of pro-MMP-9 by removal of the propeptide
may occur through several proteolytic mechanisms. It is
well known that it can be processed and further activated
through a proteolytic cascade involving plasminogen, MMP-
3 and MMP-1 [13, 47–49]. Interestingly, an accumulation of
urokinase-type plasminogen activator receptor (uPAR) and
MMP-1 has been described in brain of patients who died
with CM [15, 50]. Furthermore, increased levels of MMP-
3 in brain and spleen were observed in the murine model of
CM previously cited [18]. Alternative mechanisms for pro-
MMP-9 activation involve MMP-2 [51] and MMP-7 [52].
These molecules have not been studied yet in humanmalaria.
However, in CMmurine models, MMP-2mRNA and protein
were upregulated in brain [18] and MMP-7 mRNA was
increased in liver but not in brain [18], whereas MMP-7
protein was increased in brain [19].
After secretion and activation,MMP-9 activity can still be
regulated by degradation or inhibition. MMP-9 is inhibited
not specifically by alpha2-macroglobulin and specifically by
TIMPs, TIMP-1 showing the highest affinity for MMP-9
[53]. Inhibition of the activated MMP-9 occurs through
interaction between the N-terminal domains of TIMP-1 and
the active site of the enzyme [54]. The C-terminal part
of MMP-9 is also involved, and seems to be responsible
for high-affinity interaction with TIMP-1 [55]. Recently,
Dietmann et al. measured serum levels of several TIMPs and
MMPs in patients with severe malaria [16] and found that
elevated TIMP-1 was associated with signs and symptoms
of severe malaria; in the same study the authors detected
increased levels ofMMP-8, but not ofMMP-9. MMP-9 is also
inhibited by a large number of synthetic compounds [56–
58]. Interestingly, antimalarial artemisinin- and artemisinin-
derived drugs also showed anti-MMP-9 properties [59–62].
Functionally, MMP-9 is able to process a large pattern of
molecules, including matrix proteins, inflammatory factors,
surface molecules, and intercellular junctions [12, 14].
Among these substrates, several have been associated to
4 Journal of Tropical Medicine
Table 1: Substrates of MMP-9 that might be critical to complicated severe malaria.
MMP-9 substrate Functional classification Effect of MMP-9 proteolytic activity References
Pro-TNF Cytokine proform Shedding [63]
Pro IL-1beta Cytokine proform Activation [64]
IL-1beta Cytokine Degradation [65]
Pro-TGF-beta Cytokine proform Activation [66]
GRO-alpha/CXCL1 Chemokine Degradation [67]
PF-4/CXCL4 Chemokine Degradation [67]
ENA-78/CXCL5 Chemokine Transient potentiation, further inhibition [68]
GCP-2/CXCL6 Chemokine No effects [68]
NAP-2/CXCL7 Chemokine Degradation [67]
IL-8/CXCL8 Chemokine Potentiation [67]
MIG/CXCL9 Chemokine Inhibition [69]
IP-10/CXCL10 Chemokine Degradation [69]
SDF-1/CXCL12 Chemokine Inhibition [70]
ICAM-1 Cell surface protein Inhibition [71]
IL-2R-alpha Cell surface protein Inhibition [72]
Occludin Intercellular junction Degradation [73]
ZO-1 Intercellular junction Degradation [74]
ZO-2 Intercellular junction Degradation (hypothesis) [75]
Claudin-1 Intercellular junction Degradation [76]
Claudin-2 Intercellular junction Degradation (hypothesis) [77]
Claudin-4 Intercellular junction Activation (hypothesis) [78]
Claudin-5 Intercellular junction Degradation (to be further investigated) [79]
Syndecan-1 Structural protein Shedding [80]
MBP Structural protein Degradation [81]
Beta-dystroglycan Structural protein Degradation [82]
severe malaria. Table 1 lists the principal MMP-9 substrates
which might be relevant for malaria studies. The indicated
molecules are either soluble factors (cytokines, chemokines)
or membrane-associated proteins (pro-TNF, cell surface
proteins, and intercellular junctions). All these molecules
appear to be crucial for the development of complications
of severe malaria, and their overbalanced regulation is often
associated to CM. This is characterized by cytoadherence
and sequestering of pRBCs to brain endothelial cells through
ICAM-1, followed by an elevated inflammatory response,
with high production of TNF and IL-1 beta, as well as
several chemokines, which might recruit mononuclear cells
and favour monocyte extravasation through the blood-brain
barrier (BBB), which appears leaky due to the disruption
of tight junctions ZO-1, claudin-5, and occludin [6, 7, 83–
90]. Thus, in order to better understand and eventually
prevent the mechanisms underlying CM, in the future it
will be certainly intriguing to investigate the effects of
MMP-9 on these molecules in complicated severe malaria
models. Interestingly, the gene induction as well as the
direct activation of MMP-9 by HZ has been demonstrated
in vitro either in mononuclear or on endothelial cells, and
an active role for HZ-dependent enhancement of soluble
TNF production by human monocytes has already been
demonstrated [23], as it will be discussed in the following
section.
4. Interactions between HZ and MMP-9
The relationship between falciparum HZ and human MMP-
9, as well as several related molecules, has been investigated
in-depth in a series of recent works. In an elegant work
Geurts et al. demonstrated that pro-MMP-9 binds directly
to the beta-haematin core of HZ through its haemopexin
domain, resulting in priming of the activation of the zy-
mogen by other MMPs [91]. In human monocytes HZ has
been reported to influence the MMP-9 gene and protein ex-
pression, as well as following protein release. Experiments by
Real Time RT-PCR have shown that HZ and HZ-containing
trophozoites enhanced the mRNA expression of MMP-9
[23]. HZ-dependent MMP-9 gene induction was also con-
firmed by additional microarray [92] and macroarray [38]
studies. As a consequence, pro-MMP-9 protein expression
was found to be increased [23]. The degranulation of gel-
atinase granules with MMP-9, lysozyme, and TIMP-1 was
also promoted, as demonstrated by data showing HZ/tro-
phozoite-dependent enhanced release of active MMP-9 [23],
lysozyme [93, 94], and TIMP-1 [94] in monocyte cell super-
natants. As a result, the total gelatinolytic activity of mono-
cytes was increased by HZ [94] and cells were able to migrate
through extracellular matrix [23].
The production of several soluble factors related to
MMP-9 has also been studied. HZ and trophozoites were
shown to stimulate the release of TNF [23] and IL-1 beta
Journal of Tropical Medicine 5
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Figure 2: HZ-containing pRBCs (trophozoites) and free HZ enhance MMP-9 levels in HUVECs. Untreated cells (column/lane 1, both
panels), cells treated with uninfected RBCs or latex as control stimuli (column/lane 2, (a) and (b) resp.), and cells treated with HZ-
containing-trophozoites or HZ (column/lane 3, (a) and (b), resp.) were incubated for 48 h. At the end of the treatment, MMP-9 levels were
measured in HUVEC supernatants by SDS-PAGE gelatin zymography and densitometric analysis through a computerized densitometer as
previously described [23, 24]. Column data (lower panels) are mean values of arbitrary densitometric units + SEM of three independent
experiments; gel data (upper panels) are from one representative experiment; the 83-kDa negative bands in the gel indicate MMP-9 levels.
Data were analyzed for significance by Student’s t-test and all differences were significant ((a) 1 versus 2: P < .02; 1 versus 3: P < .001; 2
versus 3: P < .002. (b) 1 versus 2: P < .001; 1 versus 3: P < .0001; 2 versus 3: P < .001).
[37] by human monocytes. These cytokines, which can
modulate the MMP-9 gene expression [95, 96], have been
shown to play a crucial role in HZ-dependent enhancement,
since the use of anti-TNF and anti-IL-1beta antibodies
abrogated the previous HZ effects on pro-MMP-9 expression
and active MMP-9 release [23, 37]. Anti-TNF antibodies
also blocked the HZ-dependent release of active lysozyme
[93]. Interestingly, pro-TNF and pro-IL-1 beta are also
two molecular substrates of MMP-9 (see Table 1); as a
consequence of cleavage by MMP-9, the soluble TNF is shed
from its membrane-bound precursor [63], whereas IL-1 beta
is directly activated after removal of the propeptide [64].
The use of a synthetic inhibitor of MMP-9 was shown to
abrogate the HZ-dependent enhancement of TNF release by
humanmonocytes [23]. Such an evidence demonstrated that
during malaria a pathological autoenhancing loop between
MMP-9 and TNF is likely, and the inhibition of MMP-9
could be particularly important in order to avoid detrimental
inflammatory effects during complicated malaria, CM above
all. On the other hand, the MMP-9 inhibitor did not
alter the HZ-enhanced release of IL-1 beta [37], suggesting
that in HZ-fed monocytes the production of IL-1 beta
precedes the MMP-9 enhancement. This hypothesis was
confirmed by recent time-dependent macroarray studies on
expression of inflammatory genes, showing that praecox
IL-1 beta mRNA expression was already present 2 h after
exposure of human monocytes to HZ; therefore, IL-1beta
was rapidly endorsed by additional transcription of other
inflammatory genes, including MMP-9, TNF, IL-1RA, and
several chemokines (IL-8/CXCL8, ENA-78/CXCL5, GRO-
alpha/CXCL1, GRObeta, GRO-gamma, MIP-1 alpha, MIP-1
beta, and MCP-1) [38]. Moreover, crossed experiments with
anti-TNF and anti-IL-1beta blocking antibodies suggested
that the production of IL-1 beta was earlier than TNF
production [37].
Recently, the effects of HZ on MMP-9 regulation have
been also studied in endothelial cells. MMP-9 protein expres-
sion and release was shown to be dose-dependently induced
de novo by HZ in HMECs and to enhance total gelatinolytic
activity; as a consequence, cells displayed morphological
changes, showing elongated shape and increased ability to
form microtubule-like structures through extracellular ma-
trix. In the same work, the enhanced expression of MMP-1
and MMP-3, two enzymes causally connected in the cascade
of activation of pro-MMP-9, was also described [97]. Addi-
tional data for endothelial cells from large calibre vessels are
described in Figure 2, showing that HZ and HZ-containing
trophozoites were able to enhance basal levels of activated
MMP-9 released in cell supernatants from HUVEC cultures.
Further studies performed either on mononuclear or
endothelial cells were aimed to clarify what component
(haem or lipid moiety) was responsible for the effects of HZ
on MMP-9 and related soluble factors described above. In
human monocytes the use of delipidized native or lipid-free
synthetic HZ did not reproduce the enhancing effects of HZ
on MMP-9 levels [37], gelatinolytic activity [94], lysozyme
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Figure 3: Putative mechanisms through which HZ and 15-HETE might promote NF-kappaB-controlled gene expression of MMP-9 and
related molecules.
release [94], and production of TNF [98], IL-1 beta [37], and
several chemokines [38], suggesting a major role for the lipid
moiety of HZ. Further investigation suggested that a valid
candidate responsible for HZ stimulatory effects could be 15-
HETE, since micromolar doses of this compound mimicked
HZ effects on all previous parameters [37, 38, 94, 98]. A role
for the lipid moiety of HZ has been also proposed to explain
the HZ effects on HMECs, since delipidized and synthetic
HZ did not affect MMP-9, MMP-3, and MMP-1 protein
expression [97].
Finally, a mechanism involving NF-kappaB activation
has been recently proposed to explain how HZ and 15-
HETE might promote the production of MMP-9 and related
molecules in human monocytes. After phagocytosis of HZ
and trophozoites, as well as stimulation with 15-HETE, the
phosphorylation and degradation of cytosolic IkappaB-alpha
protein and the following nuclear translocation of the NF-
kappaB complex were promoted either in short-term (2 h
after phagocytosis) or long-term (24 h after phagocytosis)
studies. These events appeared directly related to HZ-
dependent enhancement of MMP-9 release and production
of TNF and IL-1 beta, since the use of NF-kappaB inhibitors
showing antimalarial properties (quercetin, artemisinin, and
parthenolide) abrogated the effects of both HZ and 15-HETE
[61]. Additionally, the same inhibitors also abrogated the 15-
HETE enhancing effects on total gelatinolytic and lysozyme
activity [94]. In another study using a monocytic cell line
(THP-1), an extract from a plant with antimalarial properties
(Punica granatum) inhibited HZ-dependent enhancement
of MMP-9 expression and secretion by blocking the NF-
kappaB-driven transcription [99]. The previous literature
data have shown that HETEs are peroxisome proliferator-
activated receptor-gamma ligands inhibiting the production
of inflammatory cytokines and suppressing the NF-kappaB
system. However, alternative mechanisms which might lead
to HETEs-driven NF-kappaB activation have also been doc-
umented. A first alternative activation of NF-kappaB is based
on HETE-mediated activation of protein kinase C [100–102]
which in turn activates IKK [103], the kinase responsible for
IkappaB-alpha phosphorylation and degradation [104], and
subsequent nuclear translocation of NF-kappaB. Transient
activation of protein kinase C by HZ [105] may thus
explain the first NF-kappaB activation peak revealed 2 h
after HZ phagocytosis. A second alternative activation of
Journal of Tropical Medicine 7
NF-kappaB [106] was found to involve MAP kinases, ERK,
and p38 cascade. The p38 cascade was also proposed for
HETEs-dependent modulation of TNF [107] and MMP-9
[108]. Interestingly, ERK-1/2 phosphorylation by HZ has
been documented in a murine system [109]. A third alter-
native activation of NF-kappaB may result from the direct
oxidation and inactivation of IkappaB by lipid hydroperox-
ides [110]. Figure 3 summarizes the putative mechanisms
throughwhich HZ andHETEsmight activate theNF-kappaB
transcription system and promote the following enhance-
ment of gene induction of MMP-9 and related cytokines.
5. Conclusions
Evidence of the involvement of MMPs in complicated severe
malaria has been emerging during the last decade, and
HZ-dependent induction of MMP-9 expression and activity
has been demonstrated in mononuclear or endothelial
cells. Since several MMP inhibitors are already available
as potential therapeutic tools in other pathologies [55–57],
MMPs should be taken in account as potential new targets
for an innovative and adjunctive therapy for severe malaria.
Abbreviations
HZ: Haemozoin
MMP: Matrix metalloproteinase
CM: Cerebral malaria
HMEC: Human microvascular endothelial cell
HUVEC: Human umbilical vein endothelial cell
BBB: Blood-brain barrier
MHC: Major histocompatibility complex
PUFA: Polyunsaturated fatty acid
HETE: Hydroxyeicosatetraenoic acid
HODE: Hydroxyoctadecadienoic acid
HNE: Hydroxynonenal
TIMP: Tissue inhibitor of metalloproteinase
TNF: Tumor necrosis factor
IL: Interleukin
ICAM: Intercellular adhesion molecule
uPAR: Urokinase-type plasminogen activator
receptor
TGF: Transforming growth factor
ZO: Zonula occludens
MBP: Mannose binding protein
GRO: Growth-regulated oncogene
PF: Platele factor
ENA: Epithelial neutrophil activating peptide
MIP: Macrophage inflammatory protein
MCP: Monocyte chemoattractant protein
GCP: Granulocyte chemotactic protein
NAP: Neutrophil attractant-activation protein
MIG: Monokine induced by interferon-gamma
IP: Interferon-gamma-inducible protein
SDF: Stromal derived factor
ET: Endothelin
HSP: Heat shock protein.
Acknowledgments
Thanks are due to Dr. Simona Cardaropoli for her help with
HUVEC cultures and to Dr. Nicoletta Basilico, Professor
Donatella Taramelli, Dr. Philippe Van den Steen and Pro-
fessor Ghislain Opdenakker for their precious suggestions
and stimulating discussions. This study was supported by
University of Torino Intramural Funds to GG, by grants from
Compagnia di San Paolo to MP in the context of the Italian
Malaria Network and by kind supplemental donation from
Mrs. Franca Squazza to MP. The authors have no conflicting
financial interests.
References
[1] S. C. Murphy and J. G. Breman, “GAPS in the childhood
malaria burden in Africa: cerebral malaria, neurological
sequelae, anemia, respiratory distress, hypoglycemia, and
complications of pregnancy,” American Journal of Tropical
Medicine and Hygiene, vol. 64, no. 1-2, pp. 57–67, 2001.
[2] A. Khadjavi, G. Giribaldi, and M. Prato, “From control to
eradication of malaria: the end of being stuck in second
gear?” Asian Pacific Journal of Tropical Medicine, vol. 3, no. 5,
pp. 412–420, 2010.
[3] H. Brown, S. Rogerson, T. Taylor et al., “Blood-brain barrier
function in cerebral malaria inMalawian children,” American
Journal of Tropical Medicine and Hygiene, vol. 64, no. 3-4,
pp. 207–213, 2001.
[4] K. T. Andrews and M. Lanzer, “Maternal malaria: Plasmod-
ium falciparum sequestration in the placenta,” Parasitology
Research, vol. 88, no. 8, pp. 715–723, 2002.
[5] J. G. Beeson, J. C. Reeder, S. J. Rogerson, and G. V. Brown,
“Parasite adhesion and immune evasion in placental malar-
ia,” Trends in Parasitology, vol. 17, no. 7, pp. 331–337, 2001.
[6] J. K. Patnaik, B. S. Das, S. K. Mishra, S. Mohanty, S. K.
Satpathy, and D. Mohanty, “Vascular clogging, mononuclear
cell margination, and enhanced vascular permeability in the
pathogenesis of human cerebral malaria,” American Journal
of Tropical Medicine and Hygiene, vol. 51, no. 5, pp. 642–647,
1994.
[7] G. E. Grau, C. D. Mackenzie, R. A. Carr et al., “Platelet
accumulation in brain microvessels in fatal pediatric cerebral
malaria,” Journal of Infectious Diseases, vol. 187, no. 3,
pp. 461–466, 2003.
[8] A. F. G. Slater, W. J. Swiggard, B. R. Orton et al., “An iron-
carboxylate bond links the heme units of malaria pigment,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 88, no. 2, pp. 325–329, 1991.
[9] H. Nagaset and J. F. Woessner, “Matrix metalloproteinases,”
Journal of Biological Chemistry, vol. 274, no. 31, pp. 21491–
21494, 1999.
[10] G. Opdenakker, P. E. Van den Steen, B. Dubois et al.,
“Gelatinase B functions as regulator and effector in leukocyte
biology,” Journal of Leukocyte Biology, vol. 69, no. 6, pp. 851–
859, 2001.
[11] G. A. Rosenberg and Y. Yang, “Vasogenic edema due to tight
junction disruption by matrix metalloproteinases in cerebral
ischemia,” Neurosurgical focus, vol. 22, no. 5, p. E4, 2007.
[12] B. Cauwe, P. E. Van den Steen, and G. Opdenakker, “The
biochemical, biological, and pathological kaleidoscope of cell
surface substrates processed by matrix metalloproteinases,”
Critical Reviews in Biochemistry and Molecular Biology,
vol. 42, no. 3, pp. 113–185, 2007.
8 Journal of Tropical Medicine
[13] M. L. Cuzner and G. Opdenakker, “Plasminogen activators
and matrix metalloproteases, mediators of extracellular
proteolysis in inflammatory demyelination of the central
nervous system,” Journal of Neuroimmunology, vol. 94, no. 1-
2, pp. 1–14, 1999.
[14] P. Van Lint and C. Libert, “Chemokine and cytokine process-
ing by matrix metalloproteinases and its effect on leukocyte
migration and inflammation,” Journal of Leukocyte Biology,
vol. 82, no. 6, pp. 1375–1381, 2007.
[15] M. H. Deininger, S. Winkler, P. G. Kremsner, R. Meyermann,
and H. J. Schluesener, “Angiogenic proteins in brains of
patients who died with cerebral malaria,” Journal of Neuroim-
munology, vol. 142, no. 1-2, pp. 101–111, 2003.
[16] A. Dietmann, R. Helbok, P. Lackner et al., “Matrix metal-
loproteinases and their tissue inhibitors (TIMPs) in Plas-
modium falciparum malaria: serum levels of TIMP-1 are
associatedwith disease severity,” Journal of InfectiousDiseases,
vol. 197, no. 11, pp. 1614–1620, 2008.
[17] M. J. Griffiths, M. J. Shafi, S. J. Popper et al., “Genomewide
analysis of the host response to malaria in Kenyan children,”
Journal of Infectious Diseases, vol. 191, no. 10, pp. 1599–1611,
2005.
[18] P. E. Van den Steen, I. Van Aelst, S. Starckx, K. Maskos,
G. Opdenakker, and A. Pagenstecher, “Matrix metallopro-
teinases, tissue inhibitors of MMPs and TACE in experimen-
tal cerebral malaria,” Laboratory Investigation, vol. 86, no. 9,
pp. 873–888, 2006.
[19] A. Szklarczyk, M. Stins, E. A. Milward et al., “Glial activation
and matrix metalloproteinase release in cerebral malaria,”
Journal of neurovirology, vol. 13, no. 1, pp. 2–10, 2007.
[20] P. L. Olliaro and D. E. Goldberg, “The Plasmodium digestive
vacuole: metabolic headquarters and choice drug target,”
Parasitology Today, vol. 11, no. 8, pp. 294–297, 1995.
[21] H. Kuhn, A. Hache, and H. Sklenar, “A structural model
for the interaction of haem with unsaturated fatty acids
explaining its quasi-lipoxygenase activity. Quantum chemical
calculations,” Biomedica Biochimica Acta, vol. 42, no. 11-12,
pp. S175–S176, 1983.
[22] E. Schwarzer, H. Ku¨hn, E. Valente, and P. Arese, “Malaria-
parasitized erythrocytes and hemozoin nonenzymatically
generate large amounts of hydroxy fatty acids that inhibit
monocyte functions,” Blood, vol. 101, no. 2, pp. 722–728,
2003.
[23] M. Prato, G. Giribaldi, M. Polimeni, V. Gallo, and P. Arese,
“Phagocytosis of hemozoin enhances matrix metalloprotein-
ase-9 activity and TNF-α production in human monocytes:
role of matrix metalloproteinases in the pathogenesis of
falciparummalaria,” Journal of Immunology, vol. 175, no. 10,
pp. 6436–6442, 2005.
[24] S. Mitola, M. Strasly, M. Prato, P. Ghia, and F. Bussolino, “IL-
12 regulates an endothelial cell-lymphocyte network: effect
on metalloproteinase-9 production,” Journal of Immunology,
vol. 171, no. 7, pp. 3725–3733, 2003.
[25] N. H. Phu, N. Day, P. T. Diep, D. J. P. Ferguson, and N. J.
White, “Intraleucocytic malaria pigment and prognosis in
severe malaria,” Transactions of the Royal Society of Tropical
Medicine and Hygiene, vol. 89, no. 2, pp. 200–204, 1995.
[26] E. Schwarzer, G. Bellomo, G. Giribaldi, D. Ulliers, and P.
Arese, “Phagocytosis of malarial pigment haemozoin by hu-
man monocytes: a confocal microscopy study,” Parasitology,
vol. 123, no. 2, pp. 125–131, 2001.
[27] P. L. Fiori, P. Rappelli, S. N. Mirkarimi, H. Ginsburg, P.
Cappuccinelli, and F. Turrini, “Reduced microbicidal and
anti-tumour activities of human monocytes after ingestion
of Plasmodium falciparum-infected red blood cells,” Parasite
Immunology, vol. 15, no. 12, pp. 647–655, 1993.
[28] E. Schwarzer, F. Turrini, D. Ulliers, G. Giribaldi, H. Ginsburg,
and P. Arese, “Impairment of macrophage functions after
ingestion of Plasmodium falciparum-infected erythrocytes or
isolated malarial pigment,” Journal of Experimental Medicine,
vol. 176, no. 4, pp. 1033–1041, 1992.
[29] E. Schwarzer, M. Alessio, D. Ulliers, and P. Arese, “Phagocy-
tosis of theMalarial Pigment, Hemozoin, Impairs Expression
of Major Histocompatibility Complex Class II Antigen,
CD54, and CD11c in Human Monocytes,” Infection and
Immunity, vol. 66, no. 4, pp. 1601–1606, 1998.
[30] E. Schwarzer, O. A. Skorokhod, V. Barrera, and P. Arese,
“Hemozoin and the humanmonocyte–a brief review of their
interactions,” Parassitologia, vol. 50, no. 1-2, pp. 143–145,
2008.
[31] O. A. Skorokhod, M. Alessio, B. Mordmu¨ller, P. Arese,
and E. Schwarzer, “Hemozoin (malarial pigment) inhibits
differentiation and maturation of human monocyte-derived
dendritic cells: a peroxisome proliferator-activated receptor-
γ-mediated effect,” Journal of Immunology, vol. 173, no. 6,
pp. 4066–4074, 2004.
[32] C. Coban, K. J. Ishii, D. J. Sullivan, and N. Kumar, “Purified
malaria pigment (hemozoin) enhances dendritic cell mat-
uration and modulates the isotype of antibodies induced
by a DNA vaccine,” Infection and Immunity, vol. 70, no. 7,
pp. 3939–3943, 2002.
[33] C. Coban, K. J. Ishii, T. Kawai et al., “Toll-like receptor 9
mediates innate immune activation by the malaria pigment
hemozoin,” Journal of Experimental Medicine, vol. 201, no. 1,
pp. 19–25, 2005.
[34] G. Giribaldi, D. Ulliers, E. Schwarzer, I. Roberts, W. Piaci-
bello, and P. Arese, “Hemozoin- and 4-hydroxynonenal-
mediated inhibition of erythropoiesis. Possible role in malar-
ial dyserythropoiesis and anemia,” Haematologica, vol. 89,
no. 4, pp. 492–493, 2004.
[35] S. Pichyangkul, P. Saengkrai, and H. K. Webster, “Plas-
modium falciparum pigment induces monocytes to release
high levels of tumor necrosis factor-α and interleukin-1β,”
American Journal of Tropical Medicine and Hygiene, vol. 51,
no. 4, pp. 430–435, 1994.
[36] B. A. Sherry, G. Alava, K. J. Tracey, J. Martiney, A. Cerami,
and A. F. G. Slater, “Malaria-specific metabolite hemozoin
mediates the release of several potent endogenous pyrogens
(TNF, MIP-1α, and MIP-1β) in vitro, and altered thermoreg-
ulation in vivo,” Journal of Inflammation, vol. 45, no. 2,
pp. 85–96, 1995.
[37] M. Prato, V. Gallo, G. Giribaldi, and P. Arese, “Phagocytosis
of haemozoin (malarial pigment) enhances metalloprotein-
ase-9 activity in human adherent monocytes: role of IL-1beta
and 15-HETE,” Malaria Journal, vol. 7, p. 157, 2008.
[38] G. Giribaldi, M. Prato, D. Ulliers et al., “Involvement of
inflammatory chemokines in survival of human monocytes
fed with malarial pigment,” Infection and Immunity, vol. 78,
no. 11, pp. 4912–4921, 2010.
[39] M. Prato, V. Gallo, E. Valente, A. Khadjavi, G.Mandili, andG.
Giribaldi, “Malarial pigment enhances Heat Shock Protein-
27 in THP-1 cells: new perspectives for in vitro studies
on monocyte apoptosis prevention,” Asian Pacific Journal of
Tropical Medicine, vol. 3, no. 12, pp. 934–938, 2010.
[40] A. K. Tripathi, D. J. Sullivan, and M. F. Stins, “Plasmodium
falciparum-infected erythrocytes increase intercellular adhe-
sion molecule 1 expression on brain endothelium through
Journal of Tropical Medicine 9
NF-κB,” Infection and Immunity, vol. 74, no. 6, pp. 3262–
3270, 2006.
[41] D. Taramelli, N. Basilico, A. M. De Palma et al., “The effect
of synthetic malaria pigment (β-haematin) on adhesion
molecule expression and interleukin-6 production by human
endothelial cells,” Transactions of the Royal Society of Tropical
Medicine and Hygiene, vol. 92, no. 1, pp. 57–62, 1998.
[42] N. Basilico, L. Speciale, S. Parapini, P. Ferrante, and D.
Taramelli, “Endothelin-1 production by a microvascular
endothelial cell line treated with Plasmodium falciparum
parasitized red blood cells,” Clinical Science, vol. 103, supple-
ment 48, pp. 464S–466S, 2002.
[43] N. Basilico, M. Mondani, S. Parapini, L. Speciale, P. Ferrante,
and D. Taramelli, “Plasmodium falciparum parasitized red
blood cells modulate the production of endothelin-1 by
human endothelial cells,” Minerva Medica, vol. 95, no. 2,
pp. 153–158, 2004.
[44] N. Basilico, S. Parapini, F. Sisto et al., “The lipid moiety of
haemozoin (Malaria Pigment) and P. falciparum parasitised
red blood cells bind synthetic and native endothelin-1,”
Journal of biomedicine & biotechnology, vol. 2010, Article ID
854927, 2010.
[45] P. E. Van den Steen, B. Dubois, I. Nelissen, P. M. Rudd, R.
A. Dwek, and G. Opdenakker, “Biochemistry and molecular
biology of gelatinase B ormatrixmetalloproteinase-9 (MMP-
9),” Critical Reviews in Biochemistry and Molecular Biology,
vol. 37, no. 6, pp. 375–536, 2002.
[46] H. C. Brown, T. T. H. Chau, N. T. H. Mai et al., “Blood-brain
barrier function in cerebral malaria and CNS infections in
Vietnam,” Neurology, vol. 55, no. 1, pp. 104–111, 2000.
[47] Y. Ogata, J. J. Enghild, and H. Nagase, “Matrix metallopro-
teinase 3 (stromelysin) activates the precursor for the human
matrix metalloproteinase 9,” Journal of Biological Chemistry,
vol. 267, no. 6, pp. 3581–3584, 1992.
[48] K. O. Suzuki, J. J. Enghild, T. Morodomi, G. Salvesen, and H.
Nagase, “Mechanisms of activation of tissue procollagenase
by matrix metalloproteinase 3 (stromelysin),” Biochemistry,
vol. 29, no. 44, pp. 10261–10270, 1990.
[49] E. Hahn-Dantona,N. Ramos-DeSimone, J. Sipley, H. Nagase,
D. L. French, and J. P. Quigley, “Activation of ProMMP-9 by
a plasmin/MMP3 cascade in a tumor cell model. Regulation
by tissue inhibitors of metalloproteinases,” Annals of the New
York Academy of Sciences, vol. 878, pp. 372–387, 1999.
[50] S. Fauser, M. H. Deininger, P. G. Kremsner et al., “Lesion
associated expression of urokinase-type plasminogen acti-
vator receptor (uPAR, CD87) in human cerebral malaria,”
Journal of Neuroimmunology, vol. 111, no. 1-2, pp. 234–240,
2000.
[51] M. Toth, I. Chvyrkova, M. M. Bernardo, S. Hernandez-
Barrantes, and R. Fridman, “Pro-MMP-9 activation by the
MT1-MMP/MMP-2 axis and MMP-3: role of TIMP-2 and
plasma membranes,” Biochemical and Biophysical Research
Communications, vol. 308, no. 2, pp. 386–395, 2003.
[52] F. Q.Wang, J. So, S. Reierstad, andD. A. Fishman, “Matrilysin
(MMP-7) promotes invasion of ovarian cancer cells by
activation of progelatinase,” International Journal of Cancer,
vol. 114, no. 1, pp. 19–31, 2005.
[53] R. Visse and H. Nagase, “Matrix metalloproteinases and
tissue inhibitors of metalloproteinases: structure, function,
and biochemistry,” Circulation Research, vol. 92, no. 8,
pp. 827–839, 2003.
[54] G. Murphy, A. Houbrechts, M. I. Cockett, R. A. Williamson,
M. O’Shea, and A. J. P. Docherty, “The N-terminal domain
of tissue inhibitor of metalloproteinases retains metallopro-
teinase inhibitory activity,” Biochemistry, vol. 30, no. 33,
pp. 8097–8102, 1991.
[55] J. P. O’Connell, F. Willenbrock, A. J. P. Docherty, D. Eaton,
and G. Murphy, “Analysis of the role of the COOH-terminal
domain in the activation, proteolytic activity, and tissue
inhibitor of metalloproteinase interactions of gelatinase B,”
Journal of Biological Chemistry, vol. 269, no. 21, pp. 14967–
14973, 1994.
[56] J. I. Levin, “The design and synthesis of aryl hydroxamic acid
inhibitors of MMPs and TACE,” Current Topics in Medicinal
Chemistry, vol. 4, no. 12, pp. 1289–1310, 2004.
[57] C. M. Overall and C. Lo´pez-Otı´n, “Strategies for MMP in-
hibition in cancer: innovations for the post-trial era,” Nature
Reviews Cancer, vol. 2, no. 9, pp. 657–672, 2002.
[58] J. Hu, P. E. Van den Steen, Q. X. A. Sang, and G. Opde-
nakker, “Matrix metalloproteinase inhibitors as therapy for
inflammatory and vascular diseases,” Nature Reviews Drug
Discovery, vol. 6, no. 6, pp. 480–498, 2007.
[59] M. Wartenberg, S. Wolf, P. Budde et al., “The antimalaria
agent artemisinin exerts antiangiogenic effects in mouse
embryonic stem cell-derived embryoid bodies,” Laboratory
Investigation, vol. 83, no. 11, pp. 1647–1655, 2003.
[60] Y. P. Hwang, H. J. Yun, H. G. Kim, E. H. Han, G. W. Lee,
and H. G. Jeong, “Suppression of PMA-induced tumor cell
invasion by dihydroartemisinin via inhibition of PKCα/Raf/
MAPKs andNF-κB/AP-1-dependent mechanisms,”Biochem-
ical Pharmacology, vol. 79, no. 12, pp. 1714–1726, 2010.
[61] M. Prato, V. Gallo, G. Giribaldi, E. Aldieri, and P. Arese, “Role
of the NF-κB transcription pathway in the haemozoin- and
15-HETE-mediated activation of matrix metalloproteinase-
9 in human adherent monocytes,” Cellular Microbiology,
vol. 12, no. 12, pp. 1780–1791, 2010.
[62] Y. Wang, Z.-Q. Huang, C.-Q. Wang et al., “Artemisinin in-
hibits extracellular matrix metalloproteinase inducer (EMM-
PRIN) and matrix metalloproteinase-9 expression via a
protein kinase Cδ/p38/extracellular signal-regulated kinase
pathway in phorbol myristate acetate-induced THP-1 ma-
crophages,” Clinical and Experimental Pharmacology and
Physiology, vol. 38, no. 1, pp. 11–18, 2011.
[63] A. J. H. Gearing, P. Beckett, M. Christodoulou et al., “Matrix
metalloproteinases and processing of pro-TNF-α,” Journal of
Leukocyte Biology, vol. 57, no. 5, pp. 774–777, 1995.
[64] U. Scho¨nbeck, F. Mach, and P. Libby, “Generation of bio-
logically active IL-1β by matrix metalloproteinases: a novel
caspase-1-independent pathway of IL-1β processing,” Journal
of Immunology, vol. 161, no. 7, pp. 3340–3346, 1998.
[65] A. Ito, A. Mukaiyama, Y. Itoh et al., “Degradation of inter-
leukin 1β by matrix metalloproteinases,” Journal of Biological
Chemistry, vol. 271, no. 25, pp. 14657–14660, 1996.
[66] Q. Yu and I. Stamenkovic, “Cell surface-localized matrix
metalloproteinase-9 proteolytically activates TGF-β and pro-
motes tumor invasion and angiogenesis,”Genes and Develop-
ment, vol. 14, no. 2, pp. 163–176, 2000.
[67] P. E. Van den Steen, P. Proost, A. Wuyts, JO. Van Damme,
and G. Opdenakker, “Neutrophil gelatinase B potentiates
interleukin-8 tenfold by aminoterminal processing, whereas
it degrades CTAP-III, PF-4, and GRO-α and leaves RANTES
andMCP-2 intact,” Blood, vol. 96, no. 8, pp. 2673–2681, 2000.
[68] P. E. Van den Steen, A. Wuyts, S. J. Husson, P. Proost, JO.
Van Damme, and G. Opdenakker, “Gelatinase B/MMP-9
and neutrophil collagenase/MMP-8 process the chemokines
10 Journal of Tropical Medicine
human GCP-2/CXCL6, ENA-78/CXCL5 and mouse GCP-
2/LIX and modulate their physiological activities,” European
Journal of Biochemistry, vol. 270, no. 18, pp. 3739–3749, 2003.
[69] P. E. Van den Steen, S. J. Husson, P. Proost, J. O. Van
Damme, and G. Opdenakker, “Carboxyterminal cleavage
of the chemokines MIG and IP-10 by gelatinase B and
neutrophil collagenase,”Biochemical and Biophysical Research
Communications, vol. 310, no. 3, pp. 889–896, 2003.
[70] G. A. McQuibban, G. S. Butler, J. H. Gong et al., “Matrix
metalloproteinase activity inactivates the CXC chemokine
stromal cell-derived factor-1,” Journal of Biological Chemistry,
vol. 276, no. 47, pp. 43503–43508, 2001.
[71] E. Fiore, C. Fusco, P. Romero, and I. Stamenkovic, “Matrix
metalloproteinase 9 (MMP-9/gelatinase B) proteolytically
cleaves ICAM-1 and participates in tumor cell resistance to
natural killer cell-mediated cytotoxicity,” Oncogene, vol. 21,
no. 34, pp. 5213–5223, 2002.
[72] B. C. Sheu, S. M. Hsu, H. N. Ho, H. C. Lien, S. C. Huang,
and R. H. Lin, “A novel role of metalloproteinase in cancer-
mediated immunosuppression,” Cancer Research, vol. 61,
no. 1, pp. 237–242, 2001.
[73] S. J. Giebel, G.Menicucci, P. G.McGuire, and A. Das, “Matrix
metalloproteinases in early diabetic retinopathy and their
role in alternation of the blood-retinal barrier,” Laboratory
Investigation, vol. 85, no. 5, pp. 597–607, 2005.
[74] M. Asahi, X. Wang, T. Mori et al., “Effects of matrix
metalloproteinase-9 gene knock-out on the proteolysis of
blood-brain barrier and white matter components after
cerebral ischemia,” Journal of Neuroscience, vol. 21, no. 19,
pp. 7724–7732, 2001.
[75] E´. Beauchesne, P. Desjardins, A. S. Hazell, and R. F.
Butterworth, “Altered expression of tight junction proteins
and matrix metalloproteinases in thiamine-deficient mouse
brain,” Neurochemistry International, vol. 55, no. 5, pp. 275–
281, 2009.
[76] H. Ichiyasu, J. M. McCormack, K. M. McCarthy, D. Dom-
bkowski, F. I. Preffer, and E. E. Schneeberger, “Matrix
metalloproteinase-9-deficient dendritic cells have impaired
migration through tracheal epithelial tight junctions,” Amer-
ican Journal of Respiratory Cell and Molecular Biology, vol. 30,
no. 6, pp. 761–770, 2004.
[77] S. Angelow, P. Zeni, B. Ho¨hn, and H. J. Galla, “Phorbol
ester induced short- and long-term permeabilization of the
blood-CSF barrier in vitro,” Brain Research, vol. 1063, no. 2,
pp. 168–179, 2005.
[78] M. Takehara, T. Nishimura, S. Mima, T. Hoshino, and T.
Mizushima, “Effect of claudin expression on paracellular
permeability, migration and invasion of colonic cancer cells,”
Biological and Pharmaceutical Bulletin, vol. 32, no. 5, pp. 825–
831, 2009.
[79] Y. I. Yang, E. Y. Estrada, J. F. Thompson, W. Liu, and
G. A. Rosenberg, “Matrix metalloproteinase-mediated dis-
ruption of tight junction proteins in cerebral vessels is
reversed by synthetic matrix metalloproteinase inhibitor in
focal ischemia in rat,” Journal of Cerebral Blood Flow and
Metabolism, vol. 27, no. 4, pp. 697–709, 2007.
[80] S. Brule, N. Charnaux, A. Sutton et al., “The shedding of
syndecan-4 and syndecan-1 from HeLa cells and human
primary macrophages is accelerated by SDF-1/CXCL12 and
mediated by the matrix metalloproteinase-9,” Glycobiology,
vol. 16, no. 6, pp. 488–501, 2006.
[81] P. Proost, J. Van Damme, and G. Opdenakker, “Leukocyte
gelatinase B cleavage releases encephalitogens from human
myelin basic protein,” Biochemical and Biophysical Research
Communications, vol. 192, no. 3, pp. 1175–1181, 1993.
[82] S. Agrawal, P. Anderson, M. Durbeej et al., “Dystroglycan is
selectively cleaved at the parenchymal basement membrane
at sites of leukocyte extravasation in experimental autoim-
mune encephalomyelitis,” Journal of Experimental Medicine,
vol. 203, no. 4, pp. 1007–1016, 2006.
[83] S. Adams, H. Brown, and G. Turner, “Breaking down the
blood-brain barrier: signaling a path to cerebral malaria?”
Trends in Parasitology, vol. 18, no. 8, pp. 360–366, 2002.
[84] H. Brown, G. Turner, S. Rogerson et al., “Cytokine expression
in the brain in human cerebral malaria,” Journal of Infectious
Diseases, vol. 180, no. 5, pp. 1742–1746, 1999.
[85] J. B. Dietrich, “The adhesion molecule ICAM-1 and its
regulation in relation with the blood-brain barrier,” Journal
of Neuroimmunology, vol. 128, no. 1-2, pp. 58–68, 2002.
[86] G. Turner, “Cerebral malaria,” Brain Pathology, vol. 7, no. 1,
pp. 569–582, 1997.
[87] N. Coltel, V. Combes, N. H. Hunt, and G. E. Grau, “Cerebral
malaria—a neurovascular pathology with many riddles still
to be solved,” Current Neurovascular Research, vol. 1, no. 2,
pp. 91–110, 2004.
[88] I. M. Medana and G. D. H. Turner, “Human cerebral
malaria and the blood-brain barrier,” International Journal
for Parasitology, vol. 36, no. 5, pp. 555–568, 2006.
[89] H. Brown, T. T. Hien, N. Day et al., “Evidence of blood-
brain barrier dysfunction in human cerebral malaria,” Neu-
ropathology and Applied Neurobiology, vol. 25, no. 4, pp. 331–
340, 1999.
[90] M. R. Gillrie, G. Krishnegowda, K. Lee et al., “Src-family
kinase-dependent disruption of endothelial barrier func-
tion by Plasmodium falciparum merozoite proteins,” Blood,
vol. 110, no. 9, pp. 3426–3435, 2007.
[91] N. Geurts, E. Martens, I. Van Aelst, P. Proost, G. Opdenakker,
and P. E. Van den Steen, “β-hematin interaction with the
hemopexin domain of gelatinase B/MMP-9 provokes auto-
catalytic processing of the propeptide, thereby priming ac-
tivation by MMP-3,” Biochemistry, vol. 47, no. 8, pp. 2689–
2699, 2008.
[92] A. C. Schrimpe and D. W. Wright, “Comparative analysis of
gene expression changes mediated by individual constituents
of hemozoin,” Chemical Research in Toxicology, vol. 22, no. 3,
pp. 433–445, 2009.
[93] M. Prato, G. Giribaldi, and P. Arese, “Hemozoin triggers
tumor necrosis factor alpha-mediated release of lysozyme
by human adherent monocytes: new evidences on leukocyte
degranulation in P. falciparummalaria,”Asian Pacific Journal
of Tropical Medicine, vol. 2, no. 3, pp. 35–40, 2009.
[94] M. Prato, E. Valente, D. Ulliers, A. Khadjavi, and G.
Giribaldi, “Quercetin, artemisinin and parthenolide abrogate
the haemozoin- and 15-HETE-enhanced activity of enzymes
released from gelatinase granules by human monocytes,” in
Proceedings of the Antimal Annual Conference, London, UK,
March 2011.
[95] M. Bond, R. P. Fabunmi, A. H. Baker, and A. C. Newby,
“Synergistic upregulation of metalloproteinase-9 by growth
factors and inflammatory cytokines: an absolute requirement
for transcription factor NF-κB,” FEBS Letters, vol. 435, no. 1,
pp. 29–34, 1998.
[96] K. Sasaki, T. Hattori, T. Fujisawa, K. Takahashi, H. Inoue,
and M. Takigawa, “Nitric oxide mediates interleukin-1-
induced gene expression of matrix metalloproteinases and
basic fibroblast growth factor in cultured rabbit articular
Journal of Tropical Medicine 11
chondrocytes,” Journal of Biochemistry, vol. 123, no. 3,
pp. 431–439, 1998.
[97] M. Prato, S. D’Alessandro, P. E. Van den Steen et al.,
“Natural haemozoin modulates matrix metalloproteinases
and induces morphological changes in humanmicrovascular
endothelium,” Cellular Microbiology. In press.
[98] M. Prato, V. Gallo, and P. Arese, “Higher production
of tumor necrosis factor alpha in hemozoin-fed-human
adherent monocytes is dependent on lipidic component of
malarial pigment: new evidences on cytokine regulation in
Plasmodium falciparum malaria,” Asian Pacific Journal of
Tropical Medicine, vol. 3, no. 2, pp. 85–89, 2010.
[99] M. Dell’Agli, G. V. Galli, M. Bulgari et al., “Ellagitannins
of the fruit rind of pomegranate (Punica granatum) antag-
onize in vitro the host inflammatory response mechanisms
involved in the onset of malaria,” Malaria Journal, vol. 9,
no. 1, 2010.
[100] D. Sharma, P. Ottino, N. G. Bazan, and H. E. Bazan, “Epi-
dermal and hepatocyte growth factors, but not keratinocyte
growth factor, modulate protein kinase Calpha translocation
to the plasma membrane through 15(S)-hydroxyeicosatet-
raenoic acid synthesis,” The Journal of Biological Chemistry,
vol. 280, no. 9, pp. 7917–7924, 2005.
[101] S. M. Wyke, J. Khal, and M. J. Tisdale, “Signalling pathways
in the induction of proteasome expression by proteolysis-
inducing factor in murine myotubes,” Cellular Signalling,
vol. 17, no. 1, pp. 67–75, 2005.
[102] F. L. Chen, X. Z. Wang, J. Y. Li, J. P. Yu, C. Y. Huang, and Z. X.
Chen, “12-Lipoxygenase induces apoptosis of human gastric
cancer AGS cells via the ERK1/2 signal pathway,” Digestive
Diseases and Sciences, vol. 53, no. 1, pp. 181–187, 2008.
[103] H. J. Smith, S. H. Wyke, and M. J. Tisdale, “Role of protein
kinase C and NF-κB in proteolysis-inducing factor-induced
proteasome expression in CC myotubes,” British Journal of
Cancer, vol. 90, no. 9, pp. 1850–1857, 2004.
[104] I. M. Verma and J. Stevenson, “IkappaB kinase: beginning,
not the end,” Proceedings of the National Academy of Science
of United States of America, vol. 94, no. 22, pp. 11758–11760,
1997.
[105] E. Schwarzer, F. Turrini, G. Giribaldi, M. Cappadoro, and
P. Arese, “Phagocytosis of P. falciparum malarial pigment
hemozoin by human monocytes inactivates monocyte pro-
tein kinase C,” Biochimica et Biophysica Acta, vol. 1181, no. 1,
pp. 51–54, 1993.
[106] J. F. Di Mari, J. I. Saada, R. C. Mifflin, J. D. Valentich, and D.
W. Powell, “HETEs enhance IL-1-mediated COX-2 expres-
sion via augmentation of message stability in human colonic
myofibroblasts,” American Journal of Physiology, vol. 293,
no. 4, pp. G719–G728, 2007.
[107] Y. Wen, J. Gu, S. K. Chakrabarti et al., “The role of 12/15-
lipoxygenase in the expression of interleukin-6 and tumor
necrosis factor-α in macrophages,” Endocrinology, vol. 148,
no. 3, pp. 1313–1322, 2007.
[108] J. Nguyen, J. Gogusev, P. Knapnougel, and B. Bauvois,
“Protein tyrosine kinase and p38 MAP kinase pathways are
involved in stimulation of matrix metalloproteinase-9 by
TNF-α in human monocytes,” Immunology Letters, vol. 106,
no. 1, pp. 34–41, 2006.
[109] M. Jaramillo, M. Godbout, and M. Olivier, “Hemozoin in-
duces macrophage chemokine expression through oxidative
stress-dependent and -independent mechanisms,” Journal of
Immunology, vol. 174, no. 1, pp. 475–484, 2005.
[110] L. Flohe´, R. Brigelius-Flohe´, C. Saliou, M. G. Traber, and L.
Packer, “Redox regulation of NF-kappa B activation,” Free
Radical Biology and Medicine, vol. 22, no. 6, pp. 1115–1126,
1997.
